B+
Bull case
20%
Probability
Target price
$33.17
Analysis reference price unavailable
Analysis 2025-11-27 · RankAlpha Sentiment AI
TNDM
Tandem Diabetes CareANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$22.80
Analysis reference price unavailable
Analysis 2025-11-27 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$12.44
Analysis reference price unavailable
Analysis 2025-11-27 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2025-11-27
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+87.4
Score
AI commentary
Market tone is mixed: recent trading is range‑bound after a modest pullback, with investors focused on near‑term earnings and margin recovery [#RankAlpha]. Analyst commentary and sector news emphasize both upside from software/recurring revenue and downside from regulatory risk, producing cautious optimism in the market [#news]. Overall retail sentiment appears neutral-to-slightly-positive given product adoption data points [#company].
RankAlpha Sentiment AI - 2025-11-27
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventQuarterly earnings report (revenue/EPS)High impact
Quarterly results and guidance can move the stock materially; market watching guidance for pump shipments and gross margins [#RankAlpha].
-catalystRegulatory action or device recallHigh impact
Adverse FDA safety findings or a device recall would likely trigger a sharp drawdown and increased liability risk [#news].
-catalystUptake of t:slim X2 and software (Control‑IQ) adoptionHigh impact
Sustained market share gains and higher recurring revenue from software/services could materially lift valuation over multiple quarters [#company].
Recommendation
N/A
No formal recommendation provided.
As of 2025-11-27 • Updated nightlySource: Internal modelMethodology